Continuer?

La page que vous recherchez est disponible en anglais.sur notre site global www.capsugel.com

Pour visiter cette page sélectioner continuer.

Continuer
Annuler

Webinars

Throughout the year, Capsugel hosts and participates in numerous webinars and virtual conferences. Each of these activities gives us an opportunity to showcase our latest products and services, build relationships with customers and partners, and share and gain invaluable insights.

1 of 14
1 of 14
Webinar

API in Capsule: A Smart Approach for Rapid Drug Development

September 29, 2016 2016-09-29 11:00:00 2016-09-29 12:00:00 America/New_York API in Capsule: A Smart Approach for Rapid Drug Development In this webinar you’ll learn value of API-in-capsule for phase I and II studies, key considerations with micro-dosing and much more. Register now! 11 AM ET (5 PM CET)

11 AM ET (5 PM CET)

Market Segment: Pharmaceutical

Micro-dosing in Today’s Pharmaceutical Industry

Micro-dosing is the procedure of dispensing precise amounts of drug substance into capsules (powder-in-capsule or PIC). 
The PIC approach can help on two levels: 1. Speed- it enables a jump start on feasibility and first-in-human studies. Valuable data is obtained to help with the drug substance’s life cycle. 2. Assessment- drug substances’ physical characteristics are ever-changing and becoming more challenging. Flow properties, particle size, hygroscopicity, and particle morphology are obstacles to overcome during formulation development. Parallel studies can be conducted to help understand the nature of the drug substance without losing valuable time during feasibility studies.

Capsugel’s proprietary Xcelodose® Precision Powder Micro-dosing System facilitates the PIC approach by providing accurate, consistent and automated fill across compound types inclusive of very low dose applications. Xcelodose Systems have become the industry standard for micro-dosing with rapid PIC manufacture and fill accuracy to 100 micrograms. Micro-dosing best practices have been developed by Xcelience, based on the experience of more than 600 batches and 200 compounds, utilizing Xcelodose Systems to reduce product development time by 13-17 weeks. 

Key Learning Objectives:

  • Value of API-in-capsule for phase I and II studies
  • Key considerations with micro-dosing
  • Case studies from different perspectives on usage- potent to low dose applications
  • Best practices- experimental and cGMP capabilities—pushing the limits and creative solutions

Presented by:

  • Mark Cappucci, Team Leader, Preformulation and Formulation Development Services, Xcelience
  • Ted Koontz, Vice President, Operations, Xcelience

Register here

Enabling Formulation of Water-Soluble and Water-Insoluble Molecules using a Lipophilic Salt Approach

September 27, 2016 2016-09-27 11:00:00 2016-09-27 12:00:00 America/New_York Enabling Formulation of Water-Soluble and Water-Insoluble Molecules using a Lipophilic Salt Approach Join Capsugel for this webcast that will describe an approach to prepare lipophilic salt forms for a range of APIs and formulate these in concentrated lipid formulations ready for oral delivery. 11 AM ET (5 PM CET)

11 AM ET (5 PM CET)

Market Segment: Pharmaceutical

Pharmaceutical salts have traditionally been used to address formulation issues, including solubility. Preliminary in vitro and in vivo studies indicate that a lipophilic salt selection approach enables lipid formulations by supporting substantially higher loadings—more than 10-fold in some cases—and increased solubilization in the GI tract than otherwise possible using free API. The use of lipophilic salt forms can give more APIs access to the well-established benefits of lipid formulations by overcoming certain product design constraints, such as the number and/or size of dosage unit.

This webcast will describe an approach to prepare lipophilic salt forms for a range of APIs and formulate these in concentrated lipid formulations ready for oral delivery. 

Key Learning Objectives:

  • Recognize the basic properties of lipophilic salt forms of API and potential innovative applications in drug delivery
  • Understand how lipophilic salt forms increase API solubility in lipid vehicles and enable the development of highly concentrated lipid formulations (supported by hydrophilic and hydrophobic API case studies)
  • Explore biopharmaceutical synergies between the lipophilic salt form and lipid formulations for increased API solubilization and absorption

Presented by:

  • Dr. Hywel Williams, Principal Scientist, Capsugel

Register here

API in Capsule: A Smart Approach for Rapid Drug Development

September 14, 2016 2016-09-14 10:00:00 2016-09-14 11:00:00 America/New_York API in Capsule: A Smart Approach for Rapid Drug Development In this webinar you’ll learn value of API-in-capsule for phase I and II studies, key considerations with micro-dosing and much more. Register now! 10 AM ET (4 PM CET)

10 AM ET (4 PM CET)

Market Segment: Pharmaceutical

Micro-dosing in Today’s Pharmaceutical Industry

Micro-dosing is the procedure of dispensing precise amounts of drug substance into capsules (powder-in-capsule or PIC). 
The PIC approach can help on two levels: 1. Speed- it enables a jump start on feasibility and first-in-human studies. Valuable data is obtained to help with the drug substance’s life cycle. 2. Assessment- drug substances’ physical characteristics are ever-changing and becoming more challenging. Flow properties, particle size, hygroscopicity, and particle morphology are obstacles to overcome during formulation development. Parallel studies can be conducted to help understand the nature of the drug substance without losing valuable time during feasibility studies.

Capsugel’s proprietary Xcelodose® Precision Powder Micro-dosing System facilitates the PIC approach by providing accurate, consistent and automated fill across compound types inclusive of very low dose applications. Xcelodose Systems have become the industry standard for micro-dosing with rapid PIC manufacture and fill accuracy to 100 micrograms. Micro-dosing best practices have been developed by Xcelience, based on the experience of more than 600 batches and 200 compounds, utilizing Xcelodose Systems to reduce product development time by 13-17 weeks. 

Key Learning Objectives:

  • Value of API-in-capsule for phase I and II studies
  • Key considerations with micro-dosing
  • Case studies from different perspectives on usage- potent to low dose applications
  • Best practices- experimental and cGMP capabilities—pushing the limits and creative solutions

Presented by:

  • Mark Cappucci, Team Leader, Preformulation and Formulation Development Services, Xcelience
  • Ted Koontz, Vice President, Operations, Xcelience

Register here

Leading Edge HPMC Capsules – Bioequivalence and Functional Performance

July 26, 2016 2016-07-26 11:00:00 2016-07-26 12:00:00 America/New_York Leading Edge HPMC Capsules – Bioequivalence and Functional Performance Join our upcoming webinar that will present new in-vivo data demonstrating the performance characteristics of the next generation of HPMC capsules and early research. Register to learn more! 11 AM ET (5 PM CET)

11 AM ET (5 PM CET)

Market Segment: Pharmaceutical

Two-piece hard shell capsules made from hydroxypropyl methylcellulose (HPMC) are emerging as an alternative to conventional gelatin capsules for oral drug delivery when there is a physical incompatibility with gelatin. A new HPMC-polymer capsule without secondary gelling agents developed through a thermo-gelation process (Vcaps Plus) has shown dissolution profiles similar to hard gelatin capsules, including pH and ionic independence.

Although HPMC capsules are used in marketed drugs, there are few comparisons of the in-vivo performance between gelatin and HPMC in literature. In this webinar, experts will present the in-vitro dissolution and an in-vivo bioequivalence study comparing the performance of the identical formulation of three different drugs in Vcaps® Plus capsules to hard gelatin capsules. In addition, the circumstances under which the same API and formulation contained in HGC and Vcaps® Plus capsules can be expected to provide equivalent performance will be discussed.

Presented by:

  • Matt Richardson, Ph.D., Manager, Pharmaceutical Business Development, Capsugel
  • Michael Morgen, Ph.D., Senior Principal Scientist, Bend Research

Register now! If this time doesn’t work for your schedule, register anyways, and we will send  you a link to the on-demand version.

Register here

Clean Label: Clear by Design - From Development to Delivery

July 13, 2016 2016-07-13 11:00:00 2016-07-13 12:00:00 America/New_York Clean Label: Clear by Design - From Development to Delivery This webinar will provide insight into the latest delivery technologies and excipients that support the growing clean label promise. Register now! 11 AM ET (5 PM CET)

11 AM ET (5 PM CET)

Market Segment: Dietary Supplement

With today’s consumer demanding transparency through a cleaner label, they want clear knowledge and understanding of the ingredients they are consuming. Supplement suppliers make choices during product development that ultimately affect the final product label. There are market ready solutions available to capture this market trend. 

This webinar will provide insight into the latest delivery technologies and excipients that support the growing clean label promise. Through case studies we will showcase the process and progress of a product developers’ choices to meet this market need. 

Please register using the link below. If this time does not work for your schedule, you can still register for the on-demand version.

Register here


Powered by Translations.com GlobalLink OneLink SoftwarePowered By OneLink